

SESSION 1 — TECHNOLOGIES THAT DRIVE OVARIAN CANCER RESEARCH

7:00 AM	REGISTRATION AND BREAKFAST PACCAR Atrium (Pigott Building)
8:15 AM	WELCOME
8:30 AM	<p>KEYNOTE PRESENTATION</p> <p>IDENTIFICATION OF GENES AND PATHWAYS THAT PREVENT GENOME INSTABILITY Richard Kolodner, PhD • <i>Ludwig Institute for Cancer Research</i></p>
9:15 AM	<p>KEYNOTE PRESENTATION</p> <p>FUNCTIONAL GENOMICS, CANCER BIOLOGY AND TARGETS William Hahn, MD, PhD • <i>Harvard Medical School & Dana-Farber Cancer Institute</i></p>
10:00 AM	BREAK
10:20 PM	<p>ABSTRACT SESSION</p> <hr/> <p>MOLECULAR GENETIC APPROACHES TO UNDERSTANDING OVARIAN CANCER William Foulkes, MBBS, PhD, FRCPC • <i>McGill University (Canada)</i></p> <hr/> <p>NETWORK-BASED STRATIFICATION: COMBINING GENOME-SCALE SOMATIC MUTATION PROFILES WITH GENETIC INTERACTION NETWORKS TO IDENTIFY CLINICALLY RELEVANT SUBTYPES IN HIGH GRADE SEROUS OVARIAN CARCINOMA John Paul Shen, MD • <i>University of California San Diego</i></p> <hr/> <p>EPITHELIAL-MESENCHYMAL TRANSITION DRIVEN BY TRANSCRIPTIONAL FEEDBACK LOOPS CONTRIBUTES TO INTERTUMORAL MOLECULAR HETEROGENEITY IN THE METASTASIS AND RELAPSE OF EPITHELIAL OVARIAN CANCER Ruby Yun-Ju Huang, MD, PhD • <i>Cancer Science Institute of Singapore & National University of Singapore</i></p> <hr/> <p>EPIGENOMIC CHARACTERIZATION OF GENE REGULATORY NETWORKS IN HUMAN OVARIAN CANCER STEM CELLS Stephanie Battle, BS • <i>University of Washington</i></p> <hr/> <p>METABOLOMIC SIGNATURES IN SERA FROM EARLY STAGE OVARIAN CANCER PATIENTS David Gaul • <i>Georgia Institute of Technology</i></p> <hr/> <p>DEVELOPMENT AND CHARACTERIZATION OF AN OVIDUCT-SPECIFIC MODEL OF HIGH-GRADE SEROUS CARCINOMA Kathleen Cho, MD • <i>University of Michigan</i></p> <hr/> <p>BMP2 REGULATES AN OVARIAN CANCER DIFFERENTIATION HIERARCHY AND PROMOTES CHEMOTHERAPY RESISTANCE Ronald Buckanovich, MD, PhD • <i>University of Michigan</i></p>
12:05 PM – 1:30PM	LUNCH BREAK Student Center, Room 160
12:30 PM – 1:30PM	LUNCH WITH THE EXPERTS Student Center, First Floor Reception Desk

Except where otherwise noted, all sessions will be in Pigott Auditorium (Pigott Building)

KEYNOTE PRESENTATION

SCREENING FOR OVARIAN CANCER: THE WAY FORWARD

Usha Menon, PhD • *University College London (United Kingdom)*

1:30 PM

INVITED SESSION PRESENTATION

BRCA TESTING IN HIGH-RISK POPULATIONS

Ranjit Manchanda, MD, MRCOG, PhD • *St. Bartholomew's Hospital & University College London (United Kingdom)*

2:15 PM

ABSTRACT SESSION

POPULATION DISTRIBUTION OF LIFETIME RISK OF OVARIAN CANCER IN THE UNITED STATES

Celeste Leigh Pearce, PhD, MPH • *University of Southern California, Keck School of Medicine*

2:45 PM

GERMLINE MUTATIONS IN CANCER SUSCEPTIBILITY GENES IN BRCA1 AND BRCA2 NEGATIVE FAMILIES WITH OVARIAN AND BREAST CANCER

Barbara Norquist, MD • *University of Washington*

BREAK

3:15 PM

ABSTRACT SESSION CONTINUED

OVARIAN CANCER RISK FACTOR ASSOCIATIONS BY TUMOR AGGRESSIVENESS IN THE OVARIAN CANCER COHORT CONSORTIUM (OC3)

Shelley Tworoger, PhD • *Harvard Medical School & Brigham and Women's Hospital*

3:35 PM

MINING THE CIRCULATING IMMUNE CELL TRANSCRIPTOME FOR OVARIAN CANCER-SPECIFIC BIOMARKERS: A PROOF OF CONCEPT STUDY

Jesus Gonzalez Bosquet, MD • *University of Iowa*

INTEGRATING GENOMICS, TRANSCRIPTOMICS, AND PROTEOMICS FOR THE DISCOVERY OF NOVEL BIOMARKERS TO COMPLEMENT CA125 IN OVARIAN CANCER EARLY DETECTION

Clayton Boldt, PhD • *University of Texas MD Anderson Cancer Center*

EPIDEMIOLOGIC PREDICTORS OF PRE-TREATMENT CA125 IN WOMEN WITH OVARIAN CANCER

Kathryn Terry, ScD • *Harvard Medical School & Brigham and Women's Hospital*

CONTRAST ENHANCED INTERLEUKIN 16 TARGETED IMAGING DETECTS OVARIAN TUMOR AT EARLY STAGE

Animesh Barua, PhD • *Rush University Medical Center*

DNA PROMOTER HYPERMETHYLATION OF HIST1H2BB AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER FOR OVARIAN CANCER

Blanca Valle, PhD • *Johns Hopkins University School of Medicine*

WRAP UP

5:05 PM

POSTER SESSION & RECEPTION *Campion Ballroom*

5:30–8:00 PM

Please see the walking route on the back cover.

SESSION 2 — STRATEGIES FOR CONTROLLING OVARIAN CANCER

7:30 AM

REGISTRATION AND BREAKFAST PACCAR Atrium (Pigott Building)

8:30 AM

KEYNOTE PRESENTATION

MECHANISTIC INSIGHTS INTO ARID1A MUTATIONS IN OVARIAN CANCER

Charles Roberts, MD, PhD • *Dana-Farber Cancer Institute & Harvard Medical School*

9:15 AM

INVITED SESSION PRESENTATION

PHYLOGENETIC PORTRAITS OF HIGH GRADE SEROUS OVARIAN CANCERS

Sohrab Shah, PhD • *University of British Columbia & Columbia Cancer Agency (Canada)*

9:45 AM

ABSTRACT SESSION

OVULATION AND EXTRAOVARIAN ORIGIN OF OVARIAN CANCER

Yang Yang-Hartwich, PhD • *Yale University School of Medicine*

THE GENOMIC LANDSCAPES OF HIGH-GRADE SEROUS OVARIAN CANCERS: CONTRASTING LONG TERM SURVIVORS AND "PLATINUM-RESISTANT" DISEASE

Yikan Wang, PhD • *British Columbia Cancer Agency (Canada)*

10:15 AM

BREAK

10:35 AM

ABSTRACT SESSION

THE SOMATIC MUTATIONAL LANDSCAPE OF ENDOMETRIOSIS ASSOCIATED OVARIAN CANCERS AND PRECURSOR LESIONS

Michael Anglesio, PhD • *University of British Columbia & British Columbia Cancer Agency (Canada)*

THE ROLE OF THE RECEPTOR TYROSINE KINASE AXL IN AN IMMUNOCOMPETENT MOUSE MODEL OF INVASIVE ENDOMETRIOID OVARIAN CANCER

Katherine Fuh, MD, PhD • *Washington University*

DNA-PKCS IS AMPLIFIED IN HIGH GRADE SEROUS OVARIAN CANCER (HGSC), CORRELATES WITH POOR OUTCOME AND DRIVES RESISTANCE TO PLATINUM THERAPY VIA THE AKT SIGNALING PATHWAY

Euan Stronach, PhD • *Imperial College London (United Kingdom)*

OVARIAN CARCINOMA CDK12 MUTATIONS MISREGULATE DNA REPAIR GENES VIA DEFICIENT FORMATION AND FUNCTION OF THE CDK12/CYCK COMPLEX

Dalibor Blazek, PhD • *Central-European Institute of Technology & Masaryk University (Czech Republic)*

OMENTAL MACROPHAGES PROMOTE OVARIAN CANCER METASTATIC COLONIZATION

Venkatesh Krishnan, PhD • *University of Chicago*

MICROENVIRONMENT MEDIATED DOWNREGULATION OF MIR-193B PROMOTES OVARIAN CANCER METASTASIS

Anirban Mitra, PhD • *Indiana University School of Medicine*

12:05 PM – 1:30PM

LUNCH BREAK Student Center, Room 160

12:30 PM – 1:30PM

LUNCH WITH THE EXPERTS Student Center, First Floor Reception Desk

KEYNOTE PRESENTATION

EPIGENETIC REPROGRAMMING OF TUMOR ANTIGENS FOR PROMOTING VACCINE EFFICACY IN HUMAN OVARIAN CANCER
 Kunle Odunsi, MD, PhD • *Roswell Park Cancer Institute*

1:30 PM

INVITED SESSION PRESENTATION

ONCOLYTIC VIRUS THERAPY
 Kah-Whye Peng, PhD • *Mayo Clinic*

2:15 PM

ABSTRACT SESSION

IMMUNOMODULATORY ANTIBODIES FOR IMMUNOTHERAPY OF OVARIAN CANCER
 Min Dai, PhD • *University of Washington*

2:45 PM

AN ADENO-ASSOCIATED VIRUS (AAV) 9 VECTOR DELIVERING MODIFIED HUMAN MULLERIAN INHIBITING SUBSTANCE (MIS) AS A GENE THERAPY FOR OVARIAN CANCER
 David Pepin, PhD • *Harvard Medical School*

BREAK

3:15 PM

ABSTRACT SESSION CONTINUED

124I-78F_c FOR IMMUNO-PET IMAGING AND IMMUNO-TOXIC THERAPY TARGETING ENDOSIALIN/TEM1 IN TUMOR VASCULATURE
 Chunsheng Li, PhD • *Perelman School of Medicine at University of Pennsylvania*

3:35 PM

VTX-2337, A TLR8 AGONIST, PLUS CHEMOTHERAPY IN RECURRENT OVARIAN CANCER: PRECLINICAL AND PHASE 1 DATA BY THE GYNECOLOGIC ONCOLOGY GROUP
 James Kyle Bryan, MD • *VentiRx Pharmaceuticals*

PHASE Ib/II WITH EXPANSION OF PATIENTS AT THE MTD STUDY OF OLAPARIB PLUS WEEKLY (METRONOMIC) CARBOPLATIN AND PACLITAXEL IN RELAPSED OVARIAN CANCER
 Saul Rivkin, MD • *Swedish Cancer Institute & Marsha Rivkin Center for Ovarian Cancer Research*

PARP INHIBITOR NANO-THERAPY IN OVARIAN CANCER MODELS
 Srinivas Sridhar, PhD • *Northeastern University*

BRCA1-IRIS INACTIVATION SENSITIZES OVARIAN TUMORS TO CISPLATIN
 Wael ElShamy, PhD • *University of Mississippi Medical Center*

MEK INHIBITION REVERSES ANTIESTROGEN RESISTANCE IN OVARIAN CANCER (OVCA) VIA ALTERATION OF CELL CYCLE PATHWAYS AND MAPK/ESTROGEN REGULATED GENE EXPRESSION
 Karina Hew, MD • *University of Miami, Sylvester Cancer Center*

WRAP UP

5:05 PM

SESSION 4 — NOVEL THERAPEUTICS FOR OVARIAN CANCER